ProfileGDS5678 / 1417298_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 85% 86% 86% 85% 88% 82% 85% 87% 84% 83% 84% 86% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7921888
GSM967853U87-EV human glioblastoma xenograft - Control 26.4676385
GSM967854U87-EV human glioblastoma xenograft - Control 36.5329286
GSM967855U87-EV human glioblastoma xenograft - Control 46.6337186
GSM967856U87-EV human glioblastoma xenograft - Control 56.3529585
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6054488
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8192382
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4087185
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7080587
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.309684
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1357883
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3432584
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4674286
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.4570786